


CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

PRODUCT NAME:	SAMPLE ID:
Strength:	Expiration Date:
Lot Number:	Total Quantity Produced:

PHYSICAL PROPERTIES	STATUS (PASS/FAIL)	METHOD
Appearance		
Color		
Aroma		

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Unit Weight		
THC by Mass		

OTHER ACTIVE INGREDIENTS**	MG/UNIT	METHOD
Palmitoylethanolamide (PEA)		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES***	STATUS (PASS/FAIL)	METHOD
Total Pesticides		

RESIDUAL SOLVENTS***	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.†

†Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Advanced Botanical Consulting & Testing Sample ID #:

**Actual analytical results obtained by Advanced Botanical Consulting & Testing, Inc. (Tustin, CA), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

***Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

This Certificate of Analysis has been generated to document product test results.
The "Prepared By" signature does not indicate finished product release for distribution.

QUALITY APPROVAL

Prepared By / Date	Approved By / Date	Status
Vandana Kothari	 <small>DocuSigned by Vandana Kothari</small> <small>I approve this document</small> <small>25-Apr-2024 10:09:04 PDT</small> <small>87A410FFF03248738900BEED0868E359</small>	PASS



April 19, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 555374
 Sample No. 1210785

SAMPLE INFORMATION

Description FP-24-0037 PlusCBD Relief Softgel 30ct SKU 607 exp 02/26
Lot Number A106710424
Category (Type) Non-Inhalable Edible (Capsule)
Received April 17, 2024

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant) ✔ Pass
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date April 17, 2024 to April 19, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Labeled mg/ serving	% Difference (mg/ serving)	Status
Δ8-THC	ND	ND	ND	ND	-	-	-
Δ9-THC	<LOQ	<LOQ	<LOQ	<LOQ	-	-	Pass
Δ9-THCA	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	-	-	-
CBD	38.31	3.831	22.96	688.93	15	53.10	-
CBDA	26.17	2.617	15.68	470.52	15	4.56	-
CBC	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	-	-	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBG	ND	ND	ND	ND	-	-	-
CBGA	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBN	ND	ND	ND	ND	-	-	-
Total THC	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
Total CBD	61.26	6.126	36.72	1101.58	-	-	-
Total Cannabinoids	61.26	6.126	36.72	1101.58	-	-	-
Sum of Cannabinoids	64.48	6.448	38.65	1159.45	-	-	-
Serving Weight (g)	0.5994						
Package Weight (g)	17.98						


Sample is tested with only filling, the average weight of the softgel is 0.8378 g and the average filling weight is 0.5994 g.

Comments

This result of this sample is confirmed with a retest.

Reported by
Anresco, Inc.

ND = None Detected
 LOD = Limit of Detection (0.1333 mg/g)
 LOQ = Limit of Quantitation (0.4000 mg/g)
 Total THC = Δ9-THC + (0.877 * Δ9-THCA)
 Total CBD = CBD + (0.877 * CBDA)
 Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]


 Ali Sweeney
 Analyst II



April 19, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

March 26, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 553948
Sample No. 1200506

SAMPLE INFORMATION

Description IP-24-0004 30mg Relief softgel inprocess bulk exp 02/26
Lot Number C2400128
Category (Type) Non-Inhalable Edible (Capsule)
Received March 13, 2024

ANALYTICAL RESULTS

Analysis PEA
Instrument LC-MS/MS
Method Micronized/ultramicrozoned palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain, Journal of Neuroinflammation 2014, 11:136
Analysis Date March 13, 2024 to March 26, 2024

Analyte	Findings (mg/softgel)
Palmitoylethanolamide	195

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Cathy Cheng
Senior Analyst

March 26, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

April 19, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 555374
 Sample No. 1210785

SAMPLE INFORMATION

Description FP-24-0037 PlusCBD Relief Softgel 30ct SKU 607 exp 02/26
Lot Number A106710424
Category (Type) Non-Inhalable Edible (Capsule)
Received April 17, 2024

ANALYTICAL RESULTS

Analysis Pesticide Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date April 17, 2024 to April 19, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.02	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.02	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.02	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Pacllobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.02	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by
Anresco, Inc.

ND = None Detected
 LOD = Limit of Detection
 LOQ = Limit of Quantitation

Ka Meng Lao

 Ka Meng Lao
 Analyst I

April 19, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

April 19, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 555374
 Sample No. 1210785

SAMPLE INFORMATION

Description FP-24-0037 PlusCBD Relief Softgel 30ct SKU 607 exp 02/26
Lot Number A106710424
Category (Type) Non-Inhalable Edible (Capsule)
Received April 17, 2024

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method MF-CHEM-32
Analysis Date April 17, 2024 to April 19, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	<LOQ	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by
Anresco, Inc.

ND = None Detected
 LOD = Limit of Detection
 LOQ = Limit of Quantitation




Jordean Vargas
 Analyst III

April 19, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

April 23, 2024

CV SCIENCES, INC.
 9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 555374
 Sample No. 1210785

SAMPLE INFORMATION

Description FP-24-0037 PlusCBD Relief Softgel 30ct SKU 607 exp 02/26
Lot Number A106710424
Received April 17, 2024

ANALYTICAL RESULTS

Analysis Date April 17, 2024 to April 23, 2024

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /1g	AOAC 2013.01
	Staph aureus	<10 cfu/g	AOAC 2003.07

Reported by
Anresco, Inc.




Allen Zhu
 Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

page 1 of 1

April 19, 2024

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 555374
Sample No. 1210785

SAMPLE INFORMATION

Description FP-24-0037 PlusCBD Relief Softgel 30ct SKU 607 exp 02/26
Lot Number A106710424
Category (Type) Non-Inhalable Edible (Capsule)
Received April 17, 2024

ANALYTICAL RESULTS

Analysis Heavy Metals ✔ Pass
Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method MF-CHEM-16
Analysis Date April 17, 2024 to April 19, 2024

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.125	ND	0.5	Pass

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Eric Tam
Senior Chemist

April 19, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate Of Completion

Envelope Id: D7F4EF20722A44B8AE417DCBDE78F924	Status: Completed
Subject: FP-24-0037 PlusCBD Relief Softgel 30ct SKU 607 exp 02/26 A106710424	
Source Envelope:	
Document Pages: 10	Signatures: 1
Certificate Pages: 1	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Enabled	Vandana Kothari
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	vandana.kothari@cvsciences.com
	IP Address: 64.207.219.137

Record Tracking

Status: Original	Holder: Vandana Kothari	Location: DocuSign
4/25/2024 8:58:36 AM	vandana.kothari@cvsciences.com	

Signer Events

Signer Events	Signature	Timestamp
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication (Required)	<i>Vandana Kothari</i> Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 4/25/2024 8:59:15 AM Viewed: 4/25/2024 8:59:42 AM Signed: 4/25/2024 9:04:33 AM

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events

Signature	Timestamp
-----------	-----------

Editor Delivery Events

Status	Timestamp
--------	-----------

Agent Delivery Events

Status	Timestamp
--------	-----------

Intermediary Delivery Events

Status	Timestamp
--------	-----------

Certified Delivery Events

Status	Timestamp
--------	-----------

Carbon Copy Events

Status	Timestamp
--------	-----------

Witness Events

Signature	Timestamp
-----------	-----------

Notary Events

Signature	Timestamp
-----------	-----------

Envelope Summary Events

Status	Timestamps
Envelope Sent	Hashed/Encrypted 4/25/2024 8:59:15 AM
Certified Delivered	Security Checked 4/25/2024 8:59:42 AM
Signing Complete	Security Checked 4/25/2024 9:04:33 AM
Completed	Security Checked 4/25/2024 9:04:33 AM

Payment Events

Status	Timestamps
--------	------------